Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations

Journal of Cardiovascular Pharmacology

Volumn 24, Issue 2, 1994, Pages S75-S84

  Fleckenstein Grun G ^a   Thimm, F ^a   Czirfuzs, A ^a   Matyas, S ^a   Frey, M ^a  

^a Physiological Institute   (Germany)

Author keywords

Arterial ca overload; Calcium antagonists; Calcium in arteriosclerosis; Conventional human coronary artery plaques; Vasoprotection

Indexed keywords

CALCIUM ANTAGONIST; DILTIAZEM; FELODIPINE; LOW DENSITY LIPOPROTEIN; NICOTINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOSCLEROSIS; ATHEROGENESIS; CALCIFICATION; CALCIUM TRANSPORT; CONFERENCE PAPER; HUMAN; HUMAN CELL; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR SMOOTH MUSCLE;

ADULT; AGED; AGED, 80 AND OVER; ANIMAL; ARTERIOSCLEROSIS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CELLS, CULTURED; CHOLECALCIFEROL; CHOLESTEROL; CORONARY VESSELS; DILTIAZEM; DISEASE MODELS, ANIMAL; HUMAN; HYPERTENSION; MIDDLE AGE; MUSCLE, SMOOTH, VASCULAR; NICOTINE; NIFEDIPINE; NITRENDIPINE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RATS, SPRAGUE-DAWLEY; RISK FACTORS; VERAPAMIL;

EID: 0028046748     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/00005344-199412001-00012     Document Type: Article

References (46)

1. Long ER. Development of our knowledge of arteriosclerosis. In: Blumenthal HT, ed. Cowdy's arteriosclerosis. A survey of the problem. 1st Ed. Springfield, IL: Charles C Thomas, 1933.
2. Flavahan NA. Atherosclerosis or lipoprotein-induced endothelial dysfunction. Potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation 1992;85: 1927-38.
3. Blumenthal HT, Larving Al, Wheeler PA. Calcification of the media of the human aorta and its relation to intimai arteriosclerosis, ageing and disease. Am J Pathol 1944;20:655.
4. Ross R. The pathogenesis of atherosclerosis-an update. N Engl J Med 1986;314:488-500.
5. Steinbrecher UP. Oxidatively modified lipoproteins. Curr Opin Lipidol 1990;1:411-5.
6. Camejo G, Hurt-Camejo E, Bondjers G. Effect of proteoglycans on lipoprotein-cell interactions: Possible contribution to atherogenesis. Curr Opin Lipidol 1990;1:431-6.
7. Yanagi H, Sasaguri Y, Sugama K, Morimatsu M, Nagase H. Production of tissue collagenase (matrix metalloproteinase I) by human aortic smooth muscle cells in response to platelet-derived growth factor. Atherosclerosis 1992;91:207-16.
8. Wennmalm A. Nitric oxide (NO) in the cardiovascular system. Blood Pressure 1992;1:135-7.
9. Taubmann MB, Rollins BJ, Poon M, et al. JE mRNA accumulates rapidly in aortic injury and in platelet-derived growth factor-stimulated vascular smooth muscle cells. Circ Res 1992;70:314-25.
10. Kehrer JP. Free radicals as mediators of tissue injury and disease. Crit Rev Toxicol 1993;23:21-48.
11. Fleckenstein-Grün G, Fleckenstein A. Calcium-a neglected key factor in arteriosclerosis. The pathogenetic role of arterial calcium overload and its prevention by calcium antagonists. Proceedings of the 1st International Duodecim Symposium “Inflammation and Atherogenesis.” Tampere. Finland, May 1991. Ann Med 1991;23:589-99.
12. Anitschkow N, Chalatow S. On experimental cholesterin steatosis and its significance in the origin of some pathological processes. Zentralbl Allgemeine Pathol Anat 1913;14:1-9.
13. Abbott RD, Wilson PWF, Kannel WB. Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. Arteriosclerosis 1988;8:207-11.
14. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
15. Stehbens WE. The controversial role of dietary cholesterol and hypercholesterolemia in coronary heart disease and atherogenesis. Pathology 1989;21:213-21.
16. 45Ca bei Ratten). In: Betz E, ed. Vascular smooth muscle. Berlin: Springer-Verlag, 1972:71-2.
17. Fleckenstein A, Fleckenstein-Grün G. Cardiovascular protection by Ca antagonists. Eur Heart J 1980;1:15-21.
18. Fleckenstein A. Calcium antagonism in heart and smooth muscle-experimental facts and therapeutic prospects. New York: John Wiley, 1983.
19. Fleckenstein A, Frey M, Fleckenstein-Grün G. Protection by calcium antagonists against experimental arterial calcinosis. In: Pyörälä K, Rapaport E, König K, Schettler G, Diehm C, eds. Secondary prevention of coronary heart disease. Stuttgart: G. Thieme Verlag, 1983:109.
20. Fleckenstein A, Frey M, Zorn J, Fleckenstein-Grün G. The role of calcium in the pathogenesis of experimental arteriosclerosis. Trends Pharmacol Sci 1987;8:496-501.
21. Fleckenstein A, Frey M, Zorn J, Fleckenstein-Grün G. Calcium, a neglected key factor in hypertension and arteriosclerosis. Experimental vasoprotection with calcium antagonists or ACE inhibitors. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, diagnosis, and management. New York: Raven Press, 1990:471-509.
22. Fleckenstein A, Frey M, Thimm F, Fleckenstein-Grün G. Excessive mural calcium overload-a predominant causal factor in the development of stenosing coronary plaques in humans. Cardiovasc Drugs Ther 1990;4:1005-14.
23. Czirfusz A, Matyas S, Fleckenstein-Grün G. Reduction by calcium antagonists of nicotine-induced net calcium uptake into aortic media cells (Wistar rats). Pflügers Arch 1992;420(suppl I):R100.
24. Stehbens WE. Reduction of serum cholesterol levels and regression of atherosclerosis. Pathology 1991;23:45-53.
25. Parmley WW, Blumlein S, Sievers R. Modification of experimental atherosclerosis by calcium-channel blockers. Am J Cardiol 1985;55:165B-71B.
26. Grün G, Fleckenstein A. Die elektro-mechanische Entkoppelung der glatten Gefaβmuskulatur als Grundprinzip der Coronardilatation durch 4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäure-dimethylester (Bay a 1040, Nifedipin). Arzneimittelforschung 1972;22:334-44.
27. Fleckenstein-Grün G, Fleckenstein A. Calcium antagonism, a basic principle in vasodilation. In: Zanchetti A, Krikler DM, eds. Calcium antagonism in cardiovascular therapy: Experience with verapamil. Amsterdam: Excerpta Medica, 1981:30-8.
28. Fleckenstein-Grün G, Frey M, Fleckenstein A. Calcium antagonists: Mechanisms and therapeutic uses. Trends Pharmacol Sci 1984;5:283-6
29. i smooth muscle. Annu Rev Physiol 1989;51:315-9.
30. Urry DW. Neutral sites for calcium ion binding to elastin and collagen: A charge neutralization theory for calcification and its relationship to atherosclerosis. Proc Natl Acad Sci USA 1971;68:810-4.
31. Fleckenstein A, Janke J, Döring HJ, Leder O. Myocardial fibre necrosis due to intracellular Ca overload-a new principle in cardiac pathophysiology. In: Dhalla NS, ed. Recent advances in studies on cardiac structure and metabolism. Vol. 4. Myocardial Biology. Baltimore: University Park Press, 1974:563-79.
32. + + supply in phasic and tonic activation of vascular smooth muscle-vasodilator efficacy of calcium antagonists. In: Berman MC, Gevers W, Opie LH, eds. Membranes and muscles. ICSU Symp Series. IRL Press, 1985;6:235-55.
33. Herzenberg H. Studien über die Wirkungsweise des bestrahlten Ergosterins (Vigantol) und die Beziehungen der von ihm gesetzten Veränderungen zur Arteriosklerose. Beitr Pathol Anat 1929;82:27-56.
34. Fleckenstein-Grün G, Thimm F, Frey M, Czirfusz A. Role of calcium in arteriosclerosis. Experimental evaluation of antiarteriosclerotic potencies of Ca antagonists. Basic Res Cardiol 1994;89(suppl I): 145-59.
35. Hass GM, Trueheart RE, Hemmens A. Experimental arteriosclerosis due to hypervitaminosis D. Am J Pathol 1960;37:521-39.
36. Eisenstein R, Zeruolis L. Vitamin-D-induced aortic calcification. Arch Pathol 1964;77:27-35.
37. Rusch NJ, Hermsmeyer K. Calcium currents are altered in the vascular muscle cell membrane of spontaneously hypertensive rats. Circ Res 1988;63:997-1002.
38. Koutouzov S, Remmal A, Girard A, Meyer P, Marche P. Increased platelet phospholipase C activity: A molecular basis for the cellular hyperactivity in primary hypertension. In: Meyer P, Marche P, eds. Blood cells and arteries in hypertension and atherosclerosis. New York: Raven Press, 1989;141.
39. Resink TJ, Bühler FR. Dysfunctions of calcium extrusion in hypertension. In: Meyer P, Marche P, eds. Blood cells and arteries in hypertension and atherosclerosis. New York: Raven Press, 1989:157-69.
40. Kanbe T, Nara Y, Tagami M, Yamori Y. Studies of hyper-tension-induced vascular hypertrophy in cultured smooth muscle cells from spontaneously hypertensive rats. Hypertension 1983;5:887-92.
41. Fleckenstein-Grün G, Frey M, Thimm F, Hofgärtner W, Fleckenstein A. Calcium overload-an important cellular mechanism in hypertension and arteriosclerosis. Drugs 1992;44(suppl l):23-30.
42. Fleckenstein-Grün G, Frey M, Thimm F, Fleckenstein A. Protective effects of various calcium antagonists against experimental arteriosclerosis. J Hum Hypertens 1992;6(suppl I):S13-18.
43. Fleckenstein A, Frey M, Fleckenstein-Grün G. Antihypertensive and arterial anticalcinotic effects of calcium antagonists. Am J Cardiol 1986;57:1D-10D.
44. Fleckenstein A, Frey M, Zom J, Fleckenstein-Grün G. Experimental basis of the long-term therapy of arterial hypertension with calcium antagonists. Am J Cardiol 1985;56: 3H-14H.
45. Fleckenstein A, Fleckenstein-Grün G, Frey M, Zom J. Future directions in the use of calcium antagonists. Am J Cardiol 1987; 59:177B-87B.
46. Schievelbein H, Londong V, Londong W, et al. Nicotine and arteriosclerosis. Z Klin Chem Klin Biochem 1970;3:190-6.